Biotage AB
STO:BIOT
Intrinsic Value
Biotage AB engages in the provision of separation and synthesis technology solutions. [ Read More ]
The intrinsic value of one BIOT stock under the Base Case scenario is 178.72 SEK. Compared to the current market price of 177.8 SEK, Biotage AB is Undervalued by 1%.
Valuation Backtest
Biotage AB
Run backtest to discover the historical profit from buying and selling BIOT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Biotage AB
Current Assets | 1.5B |
Cash & Short-Term Investments | 683m |
Receivables | 364m |
Other Current Assets | 443m |
Non-Current Assets | 3.7B |
Long-Term Investments | 25m |
PP&E | 292m |
Intangibles | 3.3B |
Other Non-Current Assets | 30m |
Current Liabilities | 691m |
Accounts Payable | 59m |
Other Current Liabilities | 632m |
Non-Current Liabilities | 567m |
Long-Term Debt | 224m |
Other Non-Current Liabilities | 343m |
Earnings Waterfall
Biotage AB
Revenue
|
2B
SEK
|
Cost of Revenue
|
-749m
SEK
|
Gross Profit
|
1.2B
SEK
|
Operating Expenses
|
-905m
SEK
|
Operating Income
|
327m
SEK
|
Other Expenses
|
-91m
SEK
|
Net Income
|
236m
SEK
|
Free Cash Flow Analysis
Biotage AB
BIOT Profitability Score
Profitability Due Diligence
Biotage AB's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Biotage AB's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
BIOT Solvency Score
Solvency Due Diligence
Biotage AB's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Biotage AB's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIOT Price Targets Summary
Biotage AB
According to Wall Street analysts, the average 1-year price target for BIOT is 209.1 SEK with a low forecast of 161.6 SEK and a high forecast of 273 SEK.
Shareholder Return
BIOT Price
Biotage AB
Average Annual Return | 16.58% |
Standard Deviation of Annual Returns | 43.44% |
Max Drawdown | -70% |
Market Capitalization | 14.2B SEK |
Shares Outstanding | 79 348 690 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biotage AB engages in the provision of separation and synthesis technology solutions. The company is headquartered in Uppsala, Uppsala and currently employs 497 full-time employees. The company went IPO on 2000-06-30. Its customers include pharmaceutical and biotechnology companies, companies within the food industry and academic institutions. The firm offers systems and services within three areas: analytical chemistry, organic chemistry and industrial resins. Biotage’s offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The Company’s offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides and its offering within industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials. As of December 31, 2013, the Company operated 12 wholly owned subsidiaries worldwide.
Contact
IPO
Employees
Officers
The intrinsic value of one BIOT stock under the Base Case scenario is 178.72 SEK.
Compared to the current market price of 177.8 SEK, Biotage AB is Undervalued by 1%.